This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AVEO Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

123.0%

Tasso di crescita degli utili

122.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	35.4%
Tasso di crescita dei ricavi	36.2%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:VPA1 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	214	48	N/A	N/A	1
12/31/2023	162	12	N/A	N/A	1
12/31/2022	110	-24	N/A	N/A	1
9/30/2022	94	-29	-23	-23	N/A
6/30/2022	79	-36	-31	-31	N/A
3/31/2022	61	-41	-47	-47	N/A
12/31/2021	42	-53	-57	-57	N/A
9/30/2021	26	-58	-58	-58	N/A
6/30/2021	14	-56	-56	-56	N/A
3/31/2021	7	-49	-45	-45	N/A
12/31/2020	6	-36	-38	-38	N/A
9/30/2020	6	-29	-33	-32	N/A
6/30/2020	28	-4	-8	-8	N/A
3/31/2020	28	0	-6	-6	N/A
12/31/2019	29	9	-3	-3	N/A
9/30/2019	30	36	-2	-2	N/A
6/30/2019	6	-3	-24	-24	N/A
3/31/2019	6	4	-27	-27	N/A
12/31/2018	5	-5	-25	-25	N/A
9/30/2018	4	-24	-22	-22	N/A
6/30/2018	6	-28	-22	-22	N/A
3/31/2018	6	-65	-20	-20	N/A
12/31/2017	8	-65	-19	-19	N/A
9/30/2017	8	-74	-23	-23	N/A
6/30/2017	4	-53	-29	-29	N/A
3/31/2017	4	-28	-26	-26	N/A
12/31/2016	3	-27	-31	-31	N/A
9/30/2016	6	-28	-24	-24	N/A
6/30/2016	20	-15	N/A	-6	N/A
3/31/2016	20	-12	N/A	-13	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: VPA1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.03%).

Guadagni vs Mercato: VPA1 is forecast to become profitable over the next 3 years, which is considered above average market growth.

Guadagni ad alta crescita: VPA1 is expected to become profitable in the next 3 years.

Ricavi vs Mercato: VPA1's revenue (36.2% per year) is forecast to grow faster than the German market (3.8% per year).

Ricavi ad alta crescita: VPA1's revenue (36.2% per year) is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if VPA1's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

AVEO Pharmaceuticals Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Recent updates

LG Chem, Ltd. (KOSE:A051910) completed the acquisition of AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO) from a group of shareholders.

AVEO Oncology Appoints Martin Birkhofer as Its Chief Medical Officer

Insufficient new directors

Third quarter 2022 earnings released: US$0.094 loss per share (vs US$0.30 loss in 3Q 2021)

Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022

AVEO Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

AVEO Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.40 loss in 2Q 2021)

AVEO Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell Microcap Value Index

AVEO Oncology Announces Updated National Comprehensive Cancer Network Clinical Practice Guidelines Elevate Fotivda (Tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced Renal Cell Carcinoma Patients

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.81 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

AVEO Pharmaceuticals, Inc. Announces Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® in Third- and Fourth-Line Renal Cell Carcinoma

Aveo Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

Aveo Oncology Highlights Recent Progress and 2022 Outlook

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.33 loss in 3Q 2020)

AVEO Oncology Announces Ficlatuzumab Grants Fast Track Designation by the U.S. FDA

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from Russell 3000E Value Index

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

CANbridge Life Sciences Ltd. and AVEO Pharmaceuticals, Inc. Terminate Collaboration and License Agreement

AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate Fotivda® in Combination with Opdivo® in Pivotal Phase 3 Tinivo-2 Trial in Io Relapsed Renal Cell Carcinoma

AVEO Oncology Announces U.S. FDA Approval of FOTIVDA (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma

AVEO Oncology Announces Appointment of Mike Ferraresso to Chief Commercial Officer

AVEO Pharmaceuticals, Inc. Appoints Corinne Epperly as Member of the Board and to Its Nominating and Governance Committee and Compensation Committee

AVEO Pharmaceuticals, Inc. Announces the Departure of Karuna Rubin, Senior Vice President and General Counsel

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (Durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

AVEO Pharmaceuticals, Inc. Announces Management Changes

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc. announced that it has received $7.499997 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

AVEO Pharmaceuticals, Inc.(NasdaqCM:AVEO) dropped from S&P Global BMI Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita